Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular Differentiation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Cellular Differentiation. Displaying page 1 of 1.
    EudraCT Number: 2016-002720-91 Sponsor Protocol Number: HBnr02 Start Date*: 2017-09-21
    Sponsor Name:CyTuVax BV
    Full Title: Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders.
    Medical condition: In a minority of the population (5-10%) standard vaccines against Hepatitis-B do not induce protective immunity, even after prolonged and repeated vaccination courses. Non- responsiveness to hepati...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003747-22 Sponsor Protocol Number: CPHE885B12201 Start Date*: 2022-08-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma
    Medical condition: Adult participants with relapsed and refractory multiple myeloma after failure of 3 or more different prior lines of therapy, including failing an immunomodulatory drug (IMiD), a proteasome inhibit...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) ES (Ongoing) IT (Ongoing) GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001041-83 Sponsor Protocol Number: FKC-009 Start Date*: 2015-04-13
    Sponsor Name:Astellas Pharma Canada Inc.
    Full Title: Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de novo Cardiac Transplant: A Comparison between Tacrolimus- and Cyclosporine- based Im...
    Medical condition: Cardiac transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10050432 Prophylaxis against heart transplant rejection LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-017257-35 Sponsor Protocol Number: R015 Start Date*: 2010-02-25
    Sponsor Name:Revotar Biopharmaceuticals AG
    Full Title: Multi-center, randomized, double-blind, placebo-controlled, cross-over Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with moderate to sever...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002806-30 Sponsor Protocol Number: M1-1188_203 Start Date*: 2014-12-09
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Nami...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Completed) DK (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000482-36 Sponsor Protocol Number: CL02-ORY-1001AML Start Date*: 2018-09-07
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.
    Medical condition: Patients with acute mieloyd leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10024349 Leukemia myeloid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002677-30 Sponsor Protocol Number: KFE2011.04 Start Date*: 2011-08-29
    Sponsor Name:Professor Hans Erik Johnsen, MD, DMSc, Department of Haematology, Aalborg Hospital
    Full Title: Preclinical phase 0 micro dose study to evaluate the effekt of R-CHOP chemotherapy on cellular gene-expression. - Establisment of a preclinical model for in vivo evaluation of molecular biological...
    Medical condition: Diffuse Large B-Cell Lymphoma, Mantlecell Lymphoma, Follicular Lymphoma, Primary Mediastinal Lymphoma, B-CLL if Rituximab is used as part of treatment.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    18.0 100000004864 10036712 Primary mediastinal large B-cell lymphoma NOS LLT
    18.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    18.0 100000004864 10016934 Follicular predominantly small cleaved cell lymphoma (Working Formulation) NOS LLT
    18.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001417-32 Sponsor Protocol Number: CNTO136ARA3005 Start Date*: 2014-06-02
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheuma...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) LT (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003951-23 Sponsor Protocol Number: AG-221-AML-005 Start Date*: 2016-07-08
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 1b/2 Open-Label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 P...
    Medical condition: Newly diagnosed acute myeloid leukemia (AML) habouring an isocitrate dehydrogenase 1 (IDH1) or an isocitrate dehydrogenase 2 (IDH2) mutation, respectively, who are not candidates to receive intensi...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PT (Completed) ES (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000550-75 Sponsor Protocol Number: RG_05-004 Start Date*: 2006-02-24
    Sponsor Name:University of Birmingham
    Full Title: Phase II Study of the Tolerability and Efficacy of the Histone Deacetylase Inhibitor Sodium Valproate given in Conjunction with 5-azacytidine and ATRA (all trans retinoic acid ) in Patients with Ac...
    Medical condition: Patients who have Acute Myeloid Leukaemia (AML) or Myelodysplasia (MDS) will be recruited to this trial
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003091-40 Sponsor Protocol Number: EMN26 Start Date*: 2020-12-04
    Sponsor Name: European Myeloma Network – EMN
    Full Title: PHASE II STUDY OF IBERDOMIDE (CC220) MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing) NL (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003586-35 Sponsor Protocol Number: 215336 Start Date*: 2022-01-25
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV-targeted immunotherapy in healthy parti...
    Medical condition: Recurrent genital herpes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10018150 Genital herpes PT
    21.1 10021881 - Infections and infestations 10073931 Genital herpes simplex PT
    24.0 10021881 - Infections and infestations 10084891 Anal herpes LLT
    20.1 10021881 - Infections and infestations 10054225 Anogenital herpes LLT
    20.1 10021881 - Infections and infestations 10018151 Genital herpes, unspecified LLT
    20.0 10021881 - Infections and infestations 10019937 Herpes genital LLT
    20.0 10021881 - Infections and infestations 10019938 Herpes genitalis LLT
    20.0 10021881 - Infections and infestations 10019997 Herpetic infection of penis LLT
    20.1 10021881 - Infections and infestations 10020003 Herpetic ulceration of vulva LLT
    20.1 10021881 - Infections and infestations 10020004 Herpetic vulvovaginitis LLT
    21.1 10021881 - Infections and infestations 10065050 Perianal herpes simplex LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) ES (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 07:53:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA